Followers | 94 |
Posts | 5160 |
Boards Moderated | 0 |
Alias Born | 12/31/2016 |
Wednesday, October 24, 2018 9:14:22 PM
Ken Frazier (Merck CEO), John Peoples (VP Global Western Markets Canada, Latin America and Western Europe at Merck Consumer Care), and Dr David Dalton (UNVC CEO) chatting it up on LinkedIn:
https://www.linkedin.com/in/david-dalton-58008952/detail/recent-activity/
Speculation brewing on SpeculatingStocks.com also:
https://speculatingstocks.com/pulse/MarkNewYork/pulse.php?n=1403773
I post facts and opinions, not investment advice.
Please conduct your own DD and trade responsibly.
Recent MRK News
- Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer • Business Wire • 09/25/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma • Business Wire • 09/25/2024 10:30:00 AM
- Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus • Business Wire • 09/24/2024 12:06:00 PM
- Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers • Business Wire • 09/20/2024 11:30:00 AM
- FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) • Business Wire • 09/18/2024 10:45:00 AM
- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial • Business Wire • 09/17/2024 10:00:00 AM
- BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) • Business Wire • 09/15/2024 02:30:00 PM
- Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma • Business Wire • 09/15/2024 12:45:00 PM
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma • Business Wire • 09/14/2024 02:35:00 PM
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer • Business Wire • 09/14/2024 02:30:00 PM
- KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma • Business Wire • 09/14/2024 07:15:00 AM
- Santé Canada approuve KEYTRUDA® pour le traitement, en monothérapie, des adultes et des enfants atteints d'une tumeur solide non résécable ou métastatique associée à une forte instabilité microsatellitaire (IMS) ou à une déficience du système d • PR Newswire (Canada) • 09/12/2024 11:00:00 AM
- Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prio • PR Newswire (Canada) • 09/12/2024 11:00:00 AM
- Merck to Participate in the Bank of America 2024 Global Healthcare Conference • Business Wire • 09/11/2024 10:45:00 AM
- Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males • Business Wire • 09/11/2024 10:30:00 AM
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial • Business Wire • 09/07/2024 03:30:00 PM
- Merck Canada et l'Alliance pharmaceutique pancanadienne (APP) concluent avec succès les négociations relatives à WELIREG® (belzutifan) • PR Newswire (Canada) • 09/05/2024 11:00:00 AM
- Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan) • PR Newswire (Canada) • 09/05/2024 11:00:00 AM
- L'utilisation de WINREVAIR® (sotatercept) est maintenant autorisée au Canada pour les adultes atteints d'hypertension artérielle pulmonaire • PR Newswire (Canada) • 09/04/2024 07:00:00 PM
- WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension • PR Newswire (Canada) • 09/04/2024 07:00:00 PM
- Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 • Business Wire • 09/04/2024 10:45:00 AM
- Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema • Business Wire • 09/04/2024 10:40:00 AM
- European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults • Business Wire • 09/03/2024 10:45:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM